

A3
encl.

step iii) in conjunction with primers specific for the poly(A) signals present in the 3' R-poly(A) sequences isolated in step ii); and
vi) confirming [confirmation of] the presence of an intact retroviral genome by amplification using primers specific for its predicted U5 and U3 regions.--

--60. (Amended) A process [Process] according to claim 59 further comprising a step vii) of detecting SAg activity associated with the retrovirus, or portions thereof, said detection being carried out according to claim 58.--

--61. (Amended) A transgenic [Transgenic] animal including in its genome non-human cells according to claim 35.--

REMARKS

This application is a continuation of PCT International Application No. PCT/EP98/04926, filed 22 July 1998, designating the United States of America and claiming priority of European Application Nos. 97112482.1, filed July 22, 1997 and 97401773.3, filed July 23, 1997.

By this Preliminary Amendment, applicants have amended the specification to recite the continuing data for the above-identified application. The amendments to the specification at pages 15, 41, 42, 47-49, and 73-77 to include the appropriate sequence identifiers (SEQ ID NOS.) are made to bring the specification of the subject application into compliance with 37 C.F.R. §§1.821 through 1.825. Accordingly, applicants maintain that the amendments to the specification raises no issue of new matter and respectfully request that this Amendment be entered.

Christophe Gerald, et al.
U.S. Serial No. 09/328,314
Filed: April 3, 1998
Page 20

By this Amendment, applicants have amended claims 1-51 and 53-61. Accordingly, upon entry of this Amendment, claims 1-61 will be pending and under examination. Applicants maintain that amended claims 1-51 and 53-61 raise no issue of new matter.

[illegible]

John P. White
Reg. No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400